CA2919690C - Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate - Google Patents

Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate Download PDF

Info

Publication number
CA2919690C
CA2919690C CA2919690A CA2919690A CA2919690C CA 2919690 C CA2919690 C CA 2919690C CA 2919690 A CA2919690 A CA 2919690A CA 2919690 A CA2919690 A CA 2919690A CA 2919690 C CA2919690 C CA 2919690C
Authority
CA
Canada
Prior art keywords
signature
pathways
cto
response
pharmacodynamic biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2919690A
Other languages
English (en)
French (fr)
Other versions
CA2919690A1 (en
Inventor
Rashida A. Karmali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tactical Therapeutics Inc
Original Assignee
Tactical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tactical Therapeutics Inc filed Critical Tactical Therapeutics Inc
Publication of CA2919690A1 publication Critical patent/CA2919690A1/en
Application granted granted Critical
Publication of CA2919690C publication Critical patent/CA2919690C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2919690A 2013-08-02 2014-07-30 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate Active CA2919690C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/957,720 2013-08-02
US13/957,720 US10378059B2 (en) 2013-08-02 2013-08-02 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
PCT/US2014/048905 WO2015017545A1 (en) 2013-08-02 2014-07-30 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate

Publications (2)

Publication Number Publication Date
CA2919690A1 CA2919690A1 (en) 2015-02-05
CA2919690C true CA2919690C (en) 2021-11-02

Family

ID=52428197

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2919690A Active CA2919690C (en) 2013-08-02 2014-07-30 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate

Country Status (9)

Country Link
US (1) US10378059B2 (enExample)
EP (1) EP3027776B1 (enExample)
JP (1) JP6913459B2 (enExample)
KR (1) KR102389934B1 (enExample)
CN (1) CN105531380B (enExample)
AU (1) AU2014296212B2 (enExample)
CA (1) CA2919690C (enExample)
IL (1) IL243894B (enExample)
WO (1) WO2015017545A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3423452B1 (en) 2016-03-01 2025-05-07 University of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
JP6889009B2 (ja) * 2017-04-13 2021-06-18 浜松ホトニクス株式会社 画像取得システム及び画像取得方法
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2227205C (en) * 1995-07-21 2007-05-01 Constantia Gruppe Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
US20030170720A1 (en) * 2001-01-23 2003-09-11 Van Der Kuyl Antoinette Cornelia Means and methods for treatment evaluation
SI1504126T1 (sl) 2002-05-03 2014-08-29 Duke University Office Of Science And Technology Postopek regulacije izraĹľanja genov
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
AU2008232732A1 (en) 2007-03-28 2008-10-09 Medarex, Inc. Methods of gene amplification and expression
JP2011515088A (ja) * 2008-03-22 2011-05-19 メルク・シャープ・エンド・ドーム・コーポレイション 増殖因子シグナル伝達経路レギュレーション状態を評価するための方法及び遺伝子発現サイン
KR101597338B1 (ko) * 2009-09-04 2016-02-24 탁티칼 떼라페우틱스 인크. 5-아미노 또는 치환된 아미노 1,2,3-트리아졸 화합물 및 이의 오로트산염 제형들의 신규한 조성물들 및 이의 제조방법
US8877785B2 (en) * 2009-09-04 2014-11-04 Tactical Therapeutics Inc Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
JP6355555B2 (ja) * 2011-04-01 2018-07-11 キアゲン Wnt/b−カテニンシグナル伝達経路に関する遺伝子発現シグネチャーおよびその使用

Also Published As

Publication number Publication date
KR20160030535A (ko) 2016-03-18
WO2015017545A1 (en) 2015-02-05
KR102389934B1 (ko) 2022-04-21
JP6913459B2 (ja) 2021-08-04
CN105531380A (zh) 2016-04-27
US20150038349A1 (en) 2015-02-05
US10378059B2 (en) 2019-08-13
AU2014296212A1 (en) 2016-02-25
EP3027776C0 (en) 2024-02-07
EP3027776B1 (en) 2024-02-07
IL243894B (en) 2020-06-30
CA2919690A1 (en) 2015-02-05
JP2016526908A (ja) 2016-09-08
IL243894A0 (en) 2016-04-21
AU2014296212B2 (en) 2020-10-22
EP3027776A4 (en) 2017-03-08
HK1220493A1 (en) 2017-05-05
EP3027776A1 (en) 2016-06-08
CN105531380B (zh) 2021-07-13

Similar Documents

Publication Publication Date Title
Shinde et al. Spleen tyrosine kinase–mediated autophagy is required for epithelial–mesenchymal plasticity and metastasis in breast cancer
Farren et al. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy
Watson et al. Transcriptomic definition of molecular subgroups of small round cell sarcomas
Wagner et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival
Rubio et al. Non-canonical integrin signaling activates EGFR and RAS-MAPK-ERK signaling in small cell lung cancer
Schulze et al. RELN signaling modulates glioblastoma growth and substrate‐dependent migration
Chandrani et al. Drug-sensitiveFGFR3 mutations in lung adenocarcinoma
Lunghi et al. The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting
CA2819399C (en) Marker for determination of sensitivity to triplet combination anti-cancer agent
Comert et al. Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era
Piccaluga et al. Molecular genetics of peripheral T-cell lymphomas
Banerjee et al. Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma
Garrido et al. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours
Harada et al. TRK inhibitors in non-small cell lung cancer
Thielhelm et al. Understanding the radiobiology of vestibular schwannomas to overcome radiation resistance
CA2919690C (en) Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
Johnson et al. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma
Song et al. Cyclin D1 expression in peripheral T-cell lymphomas
Krulikas et al. Application of integrated drug screening/kinome analysis to identify inhibitors of gemcitabine-resistant pancreatic cancer cell growth
Kim et al. Randomized, two‐arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045
Wu et al. Single-cell intratumoral stemness analysis reveals the involvement of cell cycle and DNA damage repair in two different types of esophageal cancer
Kiura et al. Osimertinib in patients with epidermal growth factor receptor T790M advanced non‐small cell lung cancer selected using cytology samples
Somers et al. CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements
Marchesini et al. Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML
Devi et al. Altered ribosomal profile in acquired resistance and reversal associates with pathological response to chemotherapy in inflammatory breast cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190514